Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Type 2 Diabetes Diagnosis

Fibromyalgia and Diabetes

Insulin Resistance and Parkinson's Disease

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Diabetes Mellitus Type 2 Pathophysiology

Insulin Medication

Diabetes in Men versus Women

What is Insulin Resistance?

Type 2 Diabetes Treatment

What is Diabetes?

Type 2 Diabetes Screening and Prevention

See more featured articles »

Insulin Resistance Pathophysiology

Insulin Resistance Diagnosis

Causes of Insulin Resistance

Insulin Resistance Treatment

Insulin Resistance Symptoms

Type 2 Diabetes Symptoms

Vitamin D and Type 2 Diabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

The Risks of Prediabetes

Living With Type 2 Diabetes

Does the Keto Diet Increase the Risk of Diabetes?

Latest Type 2 Diabetes News and Research

Stricter glucose control may affect quality of life in people living with diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in people living with diabetes (type 1 or 2) using data from continuous glucose monitoring (CGM) devices paired with daily quality-of-life ratings, days with more widely fluctuating glucose readings (while still within safe limits) are followed by days with a better quality life compared to days with more stricter control– suggesting the burden of that stricter control could be preventing those individuals with stricter control from enjoying various activities.

11 Sep 2026

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults

11 Sep 2026

Healthy checkout ordinance linked to lower soda and candy sales

A new study found that a healthy checkout ordinance implemented in Berkeley, Calif. supermarkets, drug stores, and mass-market retailers in 2021 was linked to notable decreases in soda sales overall and small-package candy in supermarkets, but greater enforcement of such policies is essential for sustained and meaningful public health benefit.

10 Sep 2026

Symptomless liver condition linked to heart and kidney disease

A common liver condition thought to be harmless could be dramatically increasing the risk of heart disease, kidney failure and premature death, according to a new review led by University of Manchester and Northern Care Alliance NHS Foundation Trust researchers.

10 Sep 2026

Gut microbiome may reveal inflammation and future disease risk better than age

Gut microbiota composition explained more variation than chronological age in nearly all inflammatory cytokines and most physiological measures examined, with specific microbial profiles linked to markedly different patterns of inflammation across adulthood. People with the Bacteroides 2 enterotype showed an inflammaging-like profile decades earlier than other groups and had a higher risk of subsequent disease, while a high-diversity microbiota profile was associated with lower inflammation and reduced disease incidence.

9 Sep 2026

Stevia tastes sweet, but does your body react as if sugar is coming?

In a randomized, double-blind crossover study, researchers tested stevia alone and with glucose in adults with normal weight, overweight, or type 2 diabetes to assess acute effects on blood glucose, insulin, gut hormones, appetite, and subsequent food intake. Stevia produced no significant changes in the measured glycemic or hormonal responses compared with water and did not significantly modify responses to glucose, while appetite and subsequent energy intake were also generally unchanged.

8 Sep 2026

Working shifts may change more than your sleep schedule

A cross-sectional analysis of 1,814 Japanese workers found that shift work was associated with lower raw seafood intake and shorter sleep patterns in both sexes, while female shift workers also consumed less milk and dairy products. Total energy intake was similar between work groups, but male shift workers were more likely to consider preference and convenience when choosing foods, highlighting potentially important differences in dietary quality and lifestyle rather than calorie intake.

8 Sep 2026

Could one amino acid help explain why men tend to live shorter lives?

A UK Biobank cohort and Mendelian randomization study involving 272,475 participants linked higher circulating tyrosine with greater all-cause mortality and genetically predicted higher tyrosine with shorter lifespan. After accounting for phenylalanine, the relationship with shorter lifespan was clearest in men, while findings in women were less consistent, suggesting a potential sex-specific role for tyrosine in longevity.

7 Sep 2026

GLP-1 treatment linked to 40% fewer asthma attacks

The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

7 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

AI chatbots wrongly reassure sleep apnea patients, study finds

In a third of cases, AI chatbots wrongly reassure sleep apnea patients that their symptoms are not serious, discouraging them from seeking a referral to a specialist, according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

6 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

Gestational diabetes history linked to earlier development of type 2 diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in women that develop type 2 diabetes (T2D), those who had gestational diabetes (GD) when pregnant are developing T2D on average almost 13 years earlier than those who did not.

3 Sep 2026

As life expectancy rises, healthy aging is more important than ever

Global disease burden is shifting toward aging-related conditions as people live longer, with these diseases now representing the largest expected lifetime health burden for newborns across all income groups. Modeling suggests that reducing aging-related disease could produce unusually large and progressively greater gains in both longevity and healthy life expectancy because improvements in survival and health reinforce one another.

3 Sep 2026

Semaglutide extended lifespan in older female mice, but that was not the only finding

Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.

3 Sep 2026

Same foods, different timing, very different glucose patterns

In a randomized crossover study of 22 healthy, normal-weight Chinese men, consuming canola oil alone or with spinach before a high-glycemic mashed-potato meal produced flatter post-meal glucose and insulin responses than spinach alone or no preload. The effects were associated with increased GLP-1 signaling and slower gastric emptying, with the findings indicating that the unsaturated oil was the primary driver of the metabolic response.

3 Sep 2026

Study links popular weight-loss drugs to increased male hair loss

Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a new study shows.

3 Sep 2026

AI learned from cardiologists’ notes, and needed far less labeled ECG data

By teaching an AI system to connect raw heart signals with the clinical insights contained in cardiologists’ reports, researchers tested whether routine ECGs could reveal more with far fewer labeled examples.

2 Sep 2026

Why addiction researchers are paying closer attention to GLP-1 drugs

A Journal of Clinical Investigation Viewpoint highlights growing evidence that GLP-1 receptor agonists, particularly semaglutide, may reduce alcohol consumption and some other substance-related outcomes by acting on brain systems involved in reward, motivation, stress, and emotion. However, the authors caution that efficacy for substance use disorders is not yet firmly established and call for further research into optimal dosing, treatment duration, patient selection, mechanisms, and effects across different addictions.

2 Sep 2026